FY2025 EPS Estimates for Climb Bio Lowered by HC Wainwright

Climb Bio, Inc. (NASDAQ:CLYM) – Analysts at HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for Climb Bio in a research note issued to investors on Thursday, December 18th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.81) per share for the year, down from their previous forecast of ($0.75). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Climb Bio’s Q4 2025 earnings at ($0.19) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.72) EPS.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03).

Several other equities analysts have also recently weighed in on the stock. William Blair started coverage on shares of Climb Bio in a research report on Thursday, October 16th. They issued an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, October 8th. BTIG Research restated a “buy” rating and set a $8.00 price objective on shares of Climb Bio in a research note on Thursday, October 16th. Finally, Wall Street Zen lowered shares of Climb Bio from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.50.

Climb Bio Trading Down 6.1%

Climb Bio stock opened at $4.60 on Monday. The firm has a market capitalization of $313.63 million, a price-to-earnings ratio of -6.05 and a beta of -0.06. The firm’s fifty day moving average price is $2.29 and its two-hundred day moving average price is $1.94. Climb Bio has a 1-year low of $1.05 and a 1-year high of $5.05.

Insider Buying and Selling at Climb Bio

In related news, Director Ra Capital Management, L.P. purchased 213,099 shares of Climb Bio stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $2.18 per share, for a total transaction of $464,555.82. Following the completion of the transaction, the director owned 3,294,856 shares in the company, valued at $7,182,786.08. This represents a 6.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.20% of the company’s stock.

Institutional Trading of Climb Bio

Several hedge funds have recently added to or reduced their stakes in CLYM. RA Capital Management L.P. bought a new position in shares of Climb Bio during the 1st quarter valued at approximately $38,332,000. Affinity Asset Advisors LLC bought a new stake in shares of Climb Bio in the 1st quarter worth approximately $1,830,000. Diadema Partners LP lifted its stake in Climb Bio by 4.8% in the second quarter. Diadema Partners LP now owns 702,135 shares of the company’s stock valued at $871,000 after purchasing an additional 32,332 shares during the last quarter. Peapod Lane Capital LLC grew its holdings in Climb Bio by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 561,866 shares of the company’s stock valued at $1,129,000 after purchasing an additional 6,199 shares during the period. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in Climb Bio in the second quarter worth $575,000. Institutional investors own 69.76% of the company’s stock.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.